Lucie Bruijn

9.1k total citations · 4 hit papers
28 papers, 6.3k citations indexed

About

Lucie Bruijn is a scholar working on Neurology, Genetics and Molecular Biology. According to data from OpenAlex, Lucie Bruijn has authored 28 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Neurology, 16 papers in Genetics and 9 papers in Molecular Biology. Recurrent topics in Lucie Bruijn's work include Amyotrophic Lateral Sclerosis Research (26 papers), Neurogenetic and Muscular Disorders Research (16 papers) and Parkinson's Disease Mechanisms and Treatments (5 papers). Lucie Bruijn is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (26 papers), Neurogenetic and Muscular Disorders Research (16 papers) and Parkinson's Disease Mechanisms and Treatments (5 papers). Lucie Bruijn collaborates with scholars based in United States, United Kingdom and Canada. Lucie Bruijn's co-authors include Don W. Cleveland, Timothy M. Miller, Jeffrey D. Rothstein, Donald L. Price, Scott Anderson, Karen Anderson, Mark W. Bêcher, Andrew G. Reaume, Megan K. Houseweart and Shinsuke Kato and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Lucie Bruijn

27 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression

2005 1.2k citations Jeffrey D. Rothstein, Sarjubhai A. Patel et al. Nature profile →
UNRAVELING THE MECHANISMS INVOLVED IN MOTOR NEURON DEGENERATION IN ALS

2004 1.2k citations Lucie Bruijn, Don W. Cleveland et al. profile →
ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions

1997 1.1k citations Lucie Bruijn, Mark W. Bêcher et al. Neuron profile →
Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1

1998 960 citations Lucie Bruijn, Megan K. Houseweart et al. Science profile →

Peers

Countries citing papers authored by Lucie Bruijn

Since Specialization

Citations

This map shows the geographic impact of Lucie Bruijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucie Bruijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucie Bruijn more than expected).

Fields of papers citing papers by Lucie Bruijn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucie Bruijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucie Bruijn. The network helps show where Lucie Bruijn may publish in the future.

Co-authorship network of co-authors of Lucie Bruijn

This figure shows the co-authorship network connecting the top 25 collaborators of Lucie Bruijn. A scholar is included among the top collaborators of Lucie Bruijn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucie Bruijn. Lucie Bruijn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large‐Scale, Multi‐Cohort Proteomic Study 2025 ·Annals of Neurology ·(unknown), Joanne Wuu, (unknown), Andrea Malaspina, Volkan Granit, (unknown), Anne Cooley, (unknown), Lili Yu, Michael Bidinosti, (unknown), (unknown), Lori L. Jennings, James D. Berry, Lucie Bruijn, Sophie Brachat, Michael Benatar	0
2	Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice 2023 ·Annals of Neurology ·Michael Benatar, Lyle W. Ostrow, Joseph W. Lewcock, Frank Bennett, Jeremy M. Shefner, Robert Bowser, Paul Larkin, Lucie Bruijn, Joanne Wuu	13
3	ALS drug development guidances and trial guidelines 2019 ·Neurology ·Jinsy Andrews, Lucie Bruijn, Jeremy M. Shefner	21
4	Modeling ALS with motor neurons derived from human induced pluripotent stem cells 2016 ·Nature Neuroscience ·Samuel Sances, Lucie Bruijn, Siddharthan Chandran, Kevin Eggan, Ritchie Ho, Joseph R. Klim, Matthew R. Livesey, Emily R. Lowry, Jeffrey D. Macklis, David J. Rushton, Cameron Sadegh, Dhruv Sareen, Hynek Wichterle, Su‐Chun Zhang, Clive N. Svendsen	201
5	The Right Therapy for Neurological Disorders: From Randomized Trials to Clinical Practice - Patients versus Investigator Expectations and Needs 2016 ·Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences ·Lucie Bruijn, (unknown)	1
6	Opportunities for improving therapy development in ALS 2014 ·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Lucie Bruijn, Merit Cudkowicz, (unknown)	8
7	Mechanisms, models and biomarkers in amyotrophic lateral sclerosis 2013 ·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Martin R. Turner, Robert Bowser, Lucie Bruijn, Luc Dupuis, Albert C. Ludolph, Michael S. McGrath, Giovanni Manfredi, Nicholas J. Maragakis, Robert G. Miller, Seth L. Pullman, Seward B. Rutkove, Pamela J. Shaw, Jeremy M. Shefner, Kenneth H. Fischbeck	120
8	Funding agencies and disease organizations: Resources and recommendations to facilitate ALS clinical research 2013 ·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·David A. Chad, Sanjay I. Bidichandani, Lucie Bruijn, J. Donald Capra, (unknown), John H. Ferguson, Denise A. Figlewicz, (unknown), Petra Kaufmann, (unknown), (unknown)	4
9	Meeting report of the International Consortium of Stem Cell Networks’ Workshop Towards Clinical Trials Using Stem Cells for Amyotrophic Lateral Sclerosis/Motor Neuron Disease 2011 ·Amyotrophic Lateral Sclerosis ·(unknown), (unknown), (unknown), Caroline Marshall, (unknown), Lucie Bruijn	6
10	Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis 2009 ·Amyotrophic Lateral Sclerosis ·Michael J. Strong, Gloria M. Grace, Morris Freedman, Cathy Lomen-Hoerth, Susan Woolley, Laura H. Goldstein, Jennifer Murphy, Christen Shoesmith, (unknown), P. Nigel Leigh, Lucie Bruijn, Paul G. Ince, Denise A. Figlewicz	435
11	Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data 2007 ·The Lancet Neurology ·Jennifer C. Schymick, Sonja W. Scholz, Hon‐Chung Fung, Angela Britton, Sampath Arepalli, J. Raphael Gibbs, Federica Lombardo, Mar Matarín, Dalia Kasperavičiūtė, Dena Hernández, Cynthia Crews, Lucie Bruijn, Jeffrey D. Rothstein, Gabriele Mora, Gabriella Restagno, Adriano Chiò, Andrew Singleton, John Hardy, Bryan J. Traynor	153
12	Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies 2006 ·Expert Review of Neurotherapeutics ·Lucie Bruijn, Merit Cudkowicz	22
13	β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression breakdown → 2005 ·Nature ·Jeffrey D. Rothstein, Sarjubhai A. Patel, Melissa R. Regan, Christine Haenggeli, Yanhua H. Huang, Dwight E. Bergles, Jin Li, (unknown), Svetlana Vidensky, (unknown), (unknown), Lucie Bruijn, Zao-zhong Su, Pankaj Gupta, Paul B. Fisher	1207
14	Distinct patterns of tau-dependent process formation in mammalian cell lines 2004 ·Neuroreport ·Lucie Bruijn, Pavan Krishnamurthy, Jean‐Marc Gallo	2
15	Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1 breakdown → 1998 ·Science ·Lucie Bruijn, Megan K. Houseweart, Shinsuke Kato, Karen Anderson, Scott Anderson, Eisaku Ohama, Andrew G. Reaume, (unknown), Don W. Cleveland	960
16	ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions breakdown → 1997 ·Neuron ·Lucie Bruijn, Mark W. Bêcher, Michael K. Lee, Kenton L. Anderson, N.A. Jenkins, Neal G. Copeland, Sangram S. Sisodia, Jeffrey D. Rothstein, David Borchelt, Donald L. Price, Don W. Cleveland	1084
17	Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant 1997 ·Proceedings of the National Academy of Sciences ·Lucie Bruijn, M. F. Beal, Mark W. Bêcher, Jörg B. Schulz, Pauline Wong, Donald L. Price, Don W. Cleveland	221
18	Sequence variants in human neurofilament proteins: Absence of linkage to familial amyotrophic lateral sclerosis 1996 ·Annals of Neurology ·(unknown), Lucie Bruijn, Zuoshang Xu, Robert H. Brown, Don W. Cleveland	57
19	Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease 1996 ·Neuropathology and Applied Neurobiology ·Lucie Bruijn, Don W. Cleveland	79
20	Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease 1996 ·Neurology ·Don W. Cleveland, Lucie Bruijn, Philip C. Wong, Joseph R. Marszalek, (unknown), Michael K. Lee, (unknown), David Borchelt, Sangram S. Sisodia, Donald L. Price	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact